Angelini Pharma to buy Catalyst Pharmaceuticals for equity value of $4.1bn

Angelini Pharma has signed a definitive agreement to acquire Catalyst Pharmaceuticals for a total equity value of nearly $4.1bn. The acquisition involves Angelini Pharma purchasing all outstanding Catalyst shares for $31.50 per share in cash. Upon acquisition, Angelini Pharma will integrate Catalyst’s portfolio and infrastructure to advance rare disease therapies. Credit: MrWinn / Shutterstock.com. Angelini Pharma has signed a definitive agreement to purchase Catalyst Pharmaceuticals for a total equity value of nearly €3.5bn ($4.1bn), marking its entrance into the US market and consolidating its focus on brain health and rare diseases. The acquisition has been approved unanimously by both companies’…

Source: Pharmaceutical Technology